Get started
Author

Haojie Dong

ORCID: 0000-0002-4502-3340
Observed ORCID: 0000-0002-4502-3340
OpenAlex ID: A5000847884
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
2020 · Kai Yuan, Xiao Wang, et al. · Acta Pharmaceutica Sinica B · 148
PDF
Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC
2023 · Haojie Dong, Xiuquan Ye, et al. · Journal of Medicinal Chemistry · 43
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
2022 · Chengliang Sun, Yao Cheng, et al. · Acta Pharmaceutica Sinica B · 43
PDF
Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance
2023 · Yasheng Zhu, Xiuquan Ye, et al. · Journal of Medicinal Chemistry · 31
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7
2020 · Wenjian Min, Zeng Hou, et al. · Bioorganic & Medicinal Chemistry · 8
Abstract 7784: Targeting PRMT7 elicits anti-AML immunity by promoting MHC-I expression
2026 · Shuaishuai Ge, Kaixiu Luo, et al. · Cancer Research
Abstract 2572: Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity
2026 · Meng Liu, Lei Zhang, et al. · Cancer Research
Works count: 7
Citation count: 273
H-index: 5
I10-index: 4
Year
Topic
Type